{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:14:17Z","timestamp":1790957657735,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T00:00:00Z","timestamp":1695600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T00:00:00Z","timestamp":1695600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["MOHW112-TDU-B-221-124007"],"award-info":[{"award-number":["MOHW112-TDU-B-221-124007"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["MOST111-2314-B-037-069-MY2"],"award-info":[{"award-number":["MOST111-2314-B-037-069-MY2"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011645","name":"Kaohsiung Medical University Chung-Ho Memorial Hospital","doi-asserted-by":"publisher","award":["KMUH111-1R04"],"award-info":[{"award-number":["KMUH111-1R04"]}],"id":[{"id":"10.13039\/501100011645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011645","name":"Kaohsiung Medical University Chung-Ho Memorial Hospital","doi-asserted-by":"publisher","award":["KMUH110-0M03"],"award-info":[{"award-number":["KMUH110-0M03"]}],"id":[{"id":"10.13039\/501100011645","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s12072-023-10576-z","type":"journal-article","created":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T15:02:27Z","timestamp":1695654147000},"page":"138-154","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Severity of fatty liver is highly correlated with the risk of hypertension and diabetes: a cross-sectional and longitudinal cohort study"],"prefix":"10.1007","volume":"18","author":[{"given":"Chin-I.","family":"Shih","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Ta","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Hsuan","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeng-Fu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Lun","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Cheng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ju","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Chien","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Yao","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Yen","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyng-Yuan","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Lun","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Feng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee-Fu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Yen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Kung","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Long","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8145-1900","authenticated-orcid":false,"given":"Ming-Lung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,25]]},"reference":[{"issue":"2","key":"10576_CR1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.cld.2023.01.019","volume":"27","author":"SA Alqahtani","year":"2023","unstructured":"Alqahtani SA, Chan WK, Yu ML. Hepatic outcomes of nonalcoholic fatty liver disease including cirrhosis and hepatocellular carcinoma. Clin Liver Dis 2023;27(2):211\u2013223. https:\/\/doi.org\/10.1016\/j.cld.2023.01.019","journal-title":"Clin Liver Dis"},{"issue":"1","key":"10576_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018;15(1):11\u201320. https:\/\/doi.org\/10.1038\/nrgastro.2017.109","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10576_CR3","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335\u20131347. https:\/\/doi.org\/10.1097\/HEP.0000000000000004","journal-title":"Hepatology"},{"issue":"6","key":"10576_CR4","doi-asserted-by":"publisher","first-page":"e1456","DOI":"10.1016\/j.cgh.2021.06.048","volume":"20","author":"ZM Younossi","year":"2022","unstructured":"Younossi ZM, Ong JP, Takahashi H, et al. A global survey of physicians knowledge about nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2022;20(6):e1456\u2013e1468. https:\/\/doi.org\/10.1016\/j.cgh.2021.06.048","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10576_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","volume":"19","author":"JV Lazarus","year":"2022","unstructured":"Lazarus JV, Mark HE, Anstee QM, et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol 2022;19(1):60\u201378. https:\/\/doi.org\/10.1038\/s41575-021-00523-4","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10576_CR6","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.bpg.2014.07.008","volume":"28","author":"P Dietrich","year":"2014","unstructured":"Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol 2014;28(4):637\u2013653. https:\/\/doi.org\/10.1016\/j.bpg.2014.07.008","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"2","key":"10576_CR7","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jacl.2015.12.026","volume":"10","author":"KT Wu","year":"2016","unstructured":"Wu KT, Kuo PL, Su SB, et al. Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol. J Clin Lipidol 2016;10(2):420-425.e1. https:\/\/doi.org\/10.1016\/j.jacl.2015.12.026","journal-title":"J Clin Lipidol"},{"issue":"12","key":"10576_CR8","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1111\/j.1440-1746.2006.04698.x","volume":"22","author":"PJ Hsiao","year":"2007","unstructured":"Hsiao PJ, Kuo KK, Shin SJ, et al. Significant correlations between severe fatty liver and risk factors for metabolic syndrome. J Gastroenterol Hepatol 2007;22(12):2118\u20132123. https:\/\/doi.org\/10.1111\/j.1440-1746.2006.04698.x","journal-title":"J Gastroenterol Hepatol"},{"issue":"11","key":"10576_CR9","doi-asserted-by":"publisher","first-page":"e0143560","DOI":"10.1371\/journal.pone.0143560","volume":"10","author":"JH Huh","year":"2015","unstructured":"Huh JH, Ahn SV, Koh SB, et al. A prospective study of fatty liver index and incident hypertension: the KoGES-ARIRANG study. PLoS\u00a0One 2015;10(11):e0143560. https:\/\/doi.org\/10.1371\/journal.pone.0143560","journal-title":"PLoS\u00a0One"},{"issue":"6","key":"10576_CR10","doi-asserted-by":"publisher","first-page":"e054891","DOI":"10.1136\/bmjopen-2021-054891","volume":"12","author":"X Tang","year":"2022","unstructured":"Tang X, Shi Y, Du J, et al. Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study. BMJ Open 2022;12(6):e054891. https:\/\/doi.org\/10.1136\/bmjopen-2021-054891","journal-title":"BMJ Open"},{"issue":"4","key":"10576_CR11","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1002\/hep.26183","volume":"57","author":"SK Park","year":"2013","unstructured":"Park SK, Seo MH, Shin HC, Ryoo JH. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology. 2013;57(4):1378\u20131383. https:\/\/doi.org\/10.1002\/hep.26183","journal-title":"Hepatology"},{"issue":"2","key":"10576_CR12","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2337\/dc17-1902","volume":"41","author":"A Mantovani","year":"2018","unstructured":"Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care 2018;41(2):372\u2013382. https:\/\/doi.org\/10.2337\/dc17-1902","journal-title":"Diabetes Care"},{"issue":"1","key":"10576_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","volume":"18","author":"S Francque","year":"2021","unstructured":"Francque S, Szabo G, Abdelmalek MF, et al. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. Nat Rev Gastroenterol Hepatol 2021;18(1):24\u201339. https:\/\/doi.org\/10.1038\/s41575-020-00366-5","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"10576_CR14","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J, International Consensus P. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014.e1. https:\/\/doi.org\/10.1053\/j.gastro.2019.11.312","journal-title":"Gastroenterology"},{"issue":"2","key":"10576_CR15","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/hep.32131","volume":"75","author":"LA van Kleef","year":"2022","unstructured":"van Kleef LA, Ayada I, Alferink LJM, Pan Q, de Knegt RJ. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: the Rotterdam study. Hepatology. 2022;75(2):419\u2013429. https:\/\/doi.org\/10.1002\/hep.32131","journal-title":"Hepatology"},{"issue":"10","key":"10576_CR16","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","volume":"19","author":"H Lee","year":"2021","unstructured":"Lee H, Lee YH, Kim SU, Kim HC. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clin Gastroenterol Hepatol 2021;19(10):2138-2147.e10. https:\/\/doi.org\/10.1016\/j.cgh.2020.12.022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10576_CR17","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1607-551X(10)70073-5","volume":"26","author":"JF Yang","year":"2010","unstructured":"Yang JF, Lin CI, Huang JF, et al. Viral hepatitis infections in southern Taiwan: a multicenter community-based study. Kaohsiung J Med Sci 2010;26(9):461\u2013469. https:\/\/doi.org\/10.1016\/S1607-551X(10)70073-5","journal-title":"Kaohsiung J Med Sci"},{"issue":"3","key":"10576_CR18","doi-asserted-by":"publisher","first-page":"e042861","DOI":"10.1136\/bmjopen-2020-042861","volume":"11","author":"PC Tsai","year":"2021","unstructured":"Tsai PC, Huang CI, Yeh ML, et al. Significant amelioration of hepatitis C virus infection in a hyperendemic area: longitudinal evidence from the COMPACT Study in Taiwan. BMJ Open 2021;11(3):e042861. https:\/\/doi.org\/10.1136\/bmjopen-2020-042861","journal-title":"BMJ Open"},{"issue":"2","key":"10576_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jhep.2012.04.004","volume":"57","author":"European Association for the Study of L","year":"2012","unstructured":"European Association for the Study of L. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012;57(2):399\u2013420. https:\/\/doi.org\/10.1016\/j.jhep.2012.04.004","journal-title":"J Hepatol"},{"issue":"4","key":"10576_CR20","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1053\/j.gastro.2006.08.020","volume":"131","author":"W Dunn","year":"2006","unstructured":"Dunn W, Angulo P, Sanderson S, et al. Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology. 2006;131(4):1057\u20131063. https:\/\/doi.org\/10.1053\/j.gastro.2006.08.020","journal-title":"Gastroenterology"},{"issue":"3","key":"10576_CR21","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/hep.24452","volume":"54","author":"R Hernaez","year":"2011","unstructured":"Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54(3):1082\u20131090. https:\/\/doi.org\/10.1002\/hep.24452","journal-title":"Hepatology"},{"issue":"5","key":"10576_CR22","doi-asserted-by":"publisher","first-page":"840","DOI":"10.14309\/ajg.0000000000002020","volume":"118","author":"CM Lee","year":"2023","unstructured":"Lee CM, Yoon EL, Nakajima A, et al. A reappraisal of the diagnostic performance of b-mode ultrasonography for mild liver steatosis. Am J Gastroenterol 2023;118(5):840\u2013847. https:\/\/doi.org\/10.14309\/ajg.0000000000002020","journal-title":"Am J Gastroenterol"},{"issue":"19","key":"10576_CR23","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines. J Am Coll Cardiol 2018;71(19):e127\u2013e248. https:\/\/doi.org\/10.1016\/j.jacc.2017.11.006","journal-title":"J Am Coll Cardiol"},{"key":"10576_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/B978-0-12-812840-4.00004-9","volume-title":"Global perspectives on childhood obesity","author":"K Love-Osborne","year":"2019","unstructured":"Love-Osborne K. Chapter 4\u2014prediabetes and type 2 diabetes: an emerging epidemic among obese youth. In Bagchi D, editor., Global perspectives on childhood obesity. 2nd ed. Cambridge: Academic Press; 2019. 37\u201347","edition":"2"},{"key":"10576_CR25","doi-asserted-by":"publisher","unstructured":"Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486\u201397. doi:https:\/\/doi.org\/10.1001\/jama.285.19.2486","DOI":"10.1001\/jama.285.19.2486"},{"key":"10576_CR26","doi-asserted-by":"publisher","first-page":"8463640","DOI":"10.1155\/2022\/8463640","volume":"2022","author":"G Li","year":"2022","unstructured":"Li G, Peng Y, Chen Z, Li H, Liu D, Ye X. Bidirectional association between hypertension and NAFLD: a systematic review and meta-analysis of observational studies. Int J Endocrinol 2022;2022:8463640. https:\/\/doi.org\/10.1155\/2022\/8463640","journal-title":"Int J Endocrinol"},{"issue":"11","key":"10576_CR27","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1111\/jgh.12643","volume":"29","author":"JH Ryoo","year":"2014","unstructured":"Ryoo JH, Suh YJ, Shin HC, Cho YK, Choi JM, Park SK. Clinical association between non-alcoholic fatty liver disease and the development of hypertension. J Gastroenterol Hepatol 2014;29(11):1926\u20131931. https:\/\/doi.org\/10.1111\/jgh.12643","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"10576_CR28","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/joim.13476","volume":"292","author":"P Kasper","year":"2022","unstructured":"Kasper P, Martin A, Meyer Zu Schwabedissen A, et al. Uncontrolled hypertension: a neglected risk in patients with NAFLD. J Intern Med 2022;292(1):162\u2013164. https:\/\/doi.org\/10.1111\/joim.13476","journal-title":"J Intern Med"},{"issue":"12","key":"10576_CR29","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1161\/01.STR.0000190894.30964.75","volume":"36","author":"G Hu","year":"2005","unstructured":"Hu G, Sarti C, Jousilahti P, et al. The impact of history of hypertension and type 2 diabetes at baseline on the incidence of stroke and stroke mortality. Stroke. 2005;36(12):2538\u20132543. https:\/\/doi.org\/10.1161\/01.STR.0000190894.30964.75","journal-title":"Stroke"},{"issue":"5","key":"10576_CR30","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.cjca.2017.12.005","volume":"34","author":"JR Petrie","year":"2018","unstructured":"Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol 2018;34(5):575\u2013584. https:\/\/doi.org\/10.1016\/j.cjca.2017.12.005","journal-title":"Can J Cardiol"},{"issue":"7","key":"10576_CR31","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1161\/STROKEAHA.106.479642","volume":"38","author":"T Ninomiya","year":"2007","unstructured":"Ninomiya T, Kubo M, Doi Y, et al. Impact of metabolic syndrome on the development of cardiovascular disease in a general Japanese population: the Hisayama study. Stroke. 2007;38(7):2063\u20132069. https:\/\/doi.org\/10.1161\/STROKEAHA.106.479642","journal-title":"Stroke"},{"issue":"5","key":"10576_CR32","doi-asserted-by":"publisher","first-page":"100322","DOI":"10.1016\/j.jhepr.2021.100322","volume":"3","author":"SM Francque","year":"2021","unstructured":"Francque SM, Marchesini G, Kautz A, et al. Non-alcoholic fatty liver disease: a patient guideline. JHEP Rep 2021;3(5):100322. https:\/\/doi.org\/10.1016\/j.jhepr.2021.100322","journal-title":"JHEP Rep"},{"key":"10576_CR33","doi-asserted-by":"publisher","first-page":"9127847","DOI":"10.1155\/2017\/9127847","volume":"2017","author":"N Toshikuni","year":"2017","unstructured":"Toshikuni N, Tsuchishima M, Fukumura A, Arisawa T, Tsutsumi M. Associations of fatty liver disease with hypertension, diabetes, and dyslipidemia: comparison between alcoholic and nonalcoholic steatohepatitis. Gastroenterol Res Pract 2017;2017:9127847. https:\/\/doi.org\/10.1155\/2017\/9127847","journal-title":"Gastroenterol Res Pract"},{"issue":"6","key":"10576_CR34","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","volume":"14","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sarin SK, Wong VW, et al. The Asian pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int 2020;14(6):889\u2013919. https:\/\/doi.org\/10.1007\/s12072-020-10094-2","journal-title":"Hepatol Int"},{"key":"10576_CR35","doi-asserted-by":"publisher","first-page":"5262560","DOI":"10.1155\/2017\/5262560","volume":"2017","author":"X Ding","year":"2017","unstructured":"Ding X, Xu Y, Wang Y, et al. Nonalcoholic fatty liver disease and associated metabolic risks of hypertension in type 2 diabetes: a cross-sectional community-based study. Int J Endocrinol 2017;2017:5262560. https:\/\/doi.org\/10.1155\/2017\/5262560","journal-title":"Int J Endocrinol"},{"key":"10576_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23126500","author":"A Przezak","year":"2022","unstructured":"Przezak A, Bielka W, Pawlik A. Hypertension and type 2 diabetes & mdash; the novel treatment possibilities. Int J Mol Sci 2022. https:\/\/doi.org\/10.3390\/ijms23126500","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10576_CR37","doi-asserted-by":"publisher","first-page":"217","DOI":"10.14218\/JCTH.2018.00021","volume":"6","author":"S Lv","year":"2018","unstructured":"Lv S, Jiang S, Liu S, Dong Q, Xin Y, Xuan S. Noninvasive quantitative detection methods of liver fat content in nonalcoholic fatty liver disease. J Clin Transl Hepatol 2018;6(2):217\u2013221. https:\/\/doi.org\/10.14218\/JCTH.2018.00021","journal-title":"J Clin Transl Hepatol"},{"issue":"7","key":"10576_CR38","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","volume":"128","author":"V Ratziu","year":"2005","unstructured":"Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128(7):1898\u20131906. https:\/\/doi.org\/10.1053\/j.gastro.2005.03.084","journal-title":"Gastroenterology"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10576-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-023-10576-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10576-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T04:40:14Z","timestamp":1707540014000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-023-10576-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,25]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10576"],"URL":"https:\/\/doi.org\/10.1007\/s12072-023-10576-z","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,25]]},"assertion":[{"value":"3 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ming-Lung Yu has received research support from Abbvie, Abbott, BMS, Gilead, Merck, and Roche diagnostics; served as a consultant of Abbvie, Abbott, BMS, Gilead, Merck, Novartis, Roche, and Roche diagnostics; and served as a speaker of Abbvie, Abbott, BMS, Gilead, Merck, Roche, and Roche diagnostics. Chin-I Shih, Kuan-Ta Wu, Meng-Hsuan Hsieh, Jeng-Fu Yang, Yi-Yu Chen, Wei-Lun Tsai, Wen-Chi Chen, Po-Cheng Liang, Yu-Ju Wei, Pei-Chien Tsai, Po-Yao Hsu, Ming-Yen Hsieh, Yi-Hung Lin, Tyng-Yuan Jang, Chih-Wen Wang, Ming-Lun Yeh, Chung-Feng Huang, Jee-Fu Huang, Chia-Yen Dai, Chi-Kung Ho, Wan-Long Chuang declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the institutional review board of KMUH.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}